SUMMARY Seventy three preterm infants weighing less than 1500 g or less than 32 weeks' gestation, or both, were allocated randomly to treatment (fresh frozen plasma 10 ml/kg on admission and at 24 hours of age) or control groups. Fifteen (41%) out of 37 control patients sustained intraventricular haemorrhage compared with five (14%) of 36 patients receiving treatment (X2=5-24, P=0-022). No difference was found in coagulation factors measured at birth or at 48 hours of age in both groups. Fresh frozen plasma appears to have a beneficial effect in the prevention of intraventricular haemorrhage.
Intraventricular haemorrhage is the most common neurological disorder in preterm infants, occurring in 30-40% of babies weighing less than 1500 g.1-3
Defects in haemostasis have been associated with the occurrence of intraventricular haemorrhage, '6 and intervention studies have produced equivocal results.7-9 These studies, however, were performed before the advent of cranial ultrasound when diagnosis was based on clinical grounds and necropsies. As infants with major intraventricular haemorrhage are at high risk of neurological handicap we conducted a randomised prospective controlled trial using fresh frozen plasma to investigate its effectiveness in preventing intraventricular haemorrhage.
Patients and methods
Each year the Regional Neonatal Unit at Leeds General Infirmary admits about 120 infants of low birthweight (less than 1500 g), of whom half are inborn. All infants weighing less than 1500 g or less than 32 weeks' gestation, or both, were considered to be eligible for the study.
On admission each child was given vitamin K 1 mg intramuscularly, and a cranial ultrasound was performed to exclude an early intraventricular haemorrhage. Each infant was allocated to a treatment or control group by the opening of a presealed envelope that randomised allocation to study groups. Blood was taken for coagulation studies, and the infants assigned to the treatment group were given fresh frozen plasma 10 ml/kg on admission and again at 24 hours of age. In both groups coagulation studies were repeated at 48 hours of age. It was not possible to perform coagulation studies on all infants because of sampling and technical difficulties.
Ultrasound scans were repeated in all infants at age 48 hours, age 7-10 days, and before discharge home. Additional scans were performed when clinically warranted; thus in all children who died scans were performed shortly before death. The scans at 7-10 days and subsequent scans were performed by a radiologist (RJA) who had no knowledge of the clinical state of the infants. When haemorrhages were identified serial scans were performed at regular intervals to grade the maximum extension of the haemorrhage according to Papile's classification."' All infants were given vitamin E from birth as prophylaxis against retrolental fibroplasia, " and any infant with an unstable intra-arterial blood pressure trace, as described by Perlman (Table 3) . Furthermore, if the seven patients who were excluded from the study are included in the analysis the degree of significance is increased. We were unable to show any difference in the coagulation studies undertaken on admission and at 48 hours of age in both groups (Table 4) . We noticed a consistent trend for infants with intraventricular haemorrhage to have a longer prothrombin time, longer partial thromboplastin time, and increased fibrin/fibrinogen degradation products at birth and at 48 hours than children without haemorrhage, though this trend was not significant. Thirteen infants died during our study; five were from the treatment group, two of whom sustained intraventricular haemorrhage. Four of the deaths from the treatment group occurred before 48 hours of age, and one of these infants had developed an intraventricular haemorrhage. In the control group eight infants died: five died before 48 hours of age, three of whom had developed intraventricular haemorrhages. Three infants from the control group died after 48 hours of age; two had developed intraventricular haemorrhages. Necropsies were undertaken in seven infants who died, and in these the diagnosis by ultrasound was confirmed.
We were unable to detect any adverse effects of our treatment; the incidence of patent ductus arteriosus, congestive cardiac failure, and necrotising enterocolitis was similar in the two groups Follow up studies have shown that infants who survive the more severe grades of intraventricular haemorrhage have only a 20% chance of being normal on follow up.'-21 Although we showed that the incidence of intraventricular haemorrhage was reduced by treatment with fresh frozen plasma, we do not know if it alters the neurological outcome for these infants. Treatment with fresh frozen plasma and other agents described previously'1'6 may only remove the marker of a neurological insult instead of preventing the insult itself. Long term follow up of our population and those of other studies will answer this question.
Our results, and those of others>6 showed that coagulation abnormalities are common in preterm infants. Fresh frozen plasma infusions reduced the incidence of intraventricular haemorrhage from 41% to 14% in infants less than 32 weeks' gestation, and we therefore recommend its routine use as a prophylaxis for this disorder. A trial of treatment with fresh frozen plasma and another plasma expanding agent will determine whether the beneficial effect described here occurs by the coagulation system or by action on the stability of the circulation. 
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